Previous 10 | Next 10 |
BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the Leerink P...
CTX-8371, a bispecific checkpoint inhibitor that simultaneously targets PD-1 and PD-L1, exhibits a novel mechanism-of-action leading to proteolytic cleavage and subsequent loss of cell surface PD-1 CTX-8371 provides enhanced anti-tumor activity relative to approved anti-PD-1 and PD-L1 the...
2024-01-05 09:26:26 ET More on Compass Therapeutics Compass Therapeutics GAAP EPS of -$0.08 Seeking Alpha’s Quant Rating on Compass Therapeutics Historical earnings data for Compass Therapeutics Financial information for Compass Therapeutics Fo...
We continue to open clinical sites and enroll patients in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC). Consistent with prior guidance, top line data from this study continue to be expected in the...
2023-11-09 12:19:50 ET More on Compass Therapeutics Compass Therapeutics: South Korean Data Is Compelling, But Needs To Be Tested In The U.S. Seeking Alpha’s Quant Rating on Compass Therapeutics Historical earnings data for Compass Therapeutics Financi...
Opened 29 clinical sites and continue to enroll patients in COMPANION-002, a U.S. Phase 2/3 study of CTX-009 in combination with Paclitaxel in patients with advanced biliary tract cancers (BTC); top line data from this study is expected in the second half of 2024 Continue to enroll and follow...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023
2023-10-13 08:00:35 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips During the pandemic era, several healthcare stocks skyrocketed. The focus was, however, on biopharma companies with an early-mover advantage related to the vaccine against Covid-19. Sentime...
2023-08-29 00:15:03 ET Summary Compass Therapeutics is developing antibody therapies for cancers, with their lead candidate being CTX-009, a dual inhibitor of VEGF-A and DLL4. The company has upcoming topline data from their colorectal cancer and biliary tract cancer programs, as ...
News, Short Squeeze, Breakout and More Instantly...
Compass Therapeutics Inc. Company Name:
CMPX Stock Symbol:
OTCMKTS Market:
Compass Therapeutics Inc. Website:
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in a fireside cha...
BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its Board of Directors has appointed Thomas Sc...
CTX-471, a novel anti-CD137 agonist antibody, demonstrated anti-tumor activity in the Company’s Phase 1 Dose Escalation and Dose Expansion, first-in-human monotherapy study in patients with metastatic or locally advanced malignancies who had progressed on approved PD-1 or PD-L1 inhibitors....